All In Biotech

Drug Trial Radar · NCT04817332

STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19

A Randomised Double-blind Placebo-controlled Trial of Brensocatib (INS1007) in Patients With Severe COVID-19

Last checked: Nov 19, 2026Latest source record: Aug 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 406 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

406

Actual

Start

Jun 5, 2020

Primary completion

Feb 28, 2021

Study completion Feb 28, 2021

Sponsor

Lead sponsor
University of DundeeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
NHS Tayside; Insmed Incorporated
First posted
Mar 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. There is currently no vaccine to prevent infection with SARS-CoV-2 and no therapeutic agent to treat COVID-19. This clinical trial is designed to evaluate the potential of Brensocatib (INS1007) as a novel host directed therapy for the treatment of adult patients hospitalized with COVID-19. The investigators hypothesise that Brensocatib, by blocking damaging neutrophil proteases, will reduce the incidence of acute lung injury and acute respiratory distress syndrome (ARDS) in patients with COVID-19, thereby resulting in improved clinical outcomes at day 15 and day 29, fewer days dependent on oxygen or mechanical ventilation, and shorter length of hospital stay. High rates of patients requiring mechanical ventilation and overwhelming intensive care unit capacity has been the major issue contributing to excess deaths in Italy and Spain during the pandemic and is likely to be a major issue in other countries such as the United Kingdom in the coming weeks. Treatments that could prevent the requirement for mechanical ventilation or shorten the duration of ICU stay by reducing the severity of ARDS are therefore the number 1 target for COVID19 therapy. The investigators recently conducted a large phase 2 study of Brensocatib in patients with bronchiectasis designed to test if treatment with Brensocatib could reduce infective exacerbations and reduce neutrophil elastase activity in the lung in bronchiectasis patients. The study met its primary endpoint of time to first exacerbation and key secondary endpoint of the frequency of exacerbations as well as showing marked reductions in neutrophil elastase concentrations in sputum. Participants will be randomised to receive Brensocatib or placebo 25mg orally once daily for 28 days.

Conditions

  • Covid19

Interventions

  • BrensocatibDrug

    Selective, competitive, and reversible inhibitor of DPP1

  • PlaceboDrug

    Matched placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of Participant Clinical Status Between Treatment ArmsTime frame: Up to 29 days

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • NHS Grampian

    Aberdeen, United Kingdom

  • Royal United Hospitals Bath NHS Foundation Trust

    Bath, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, United Kingdom

  • Cardiff & Vale University Health Board

    Cardiff, United Kingdom

  • NHS Tayside

    Dundee, United Kingdom

  • NHS Fife

    Dunfermline, United Kingdom

  • Frimley Health NHS Foundation Trust

    Frimley, United Kingdom

  • Princess Alexandra Hospital NHS Trust

    Harlow, United Kingdom

  • NHS Highland

    Inverness, United Kingdom

  • NHS Forth Valley

    Larbert, United Kingdom

  • University Hospitals of Leicester NHS Trust

    Leicester, United Kingdom

  • Liverpool University Hospitals NHS Foundation Trust

    Liverpool, United Kingdom

  • Portsmouth Hospitals NHS Trust

    Portsmouth, United Kingdom

  • Sheffield Teaching Hospitals NHS Foundation Trust

    Sheffield, United Kingdom

  • University Hospitals North Midlands NHS Trust

    Stoke-on-Trent, United Kingdom

  • NHS Lanarkshire

    Wishaw, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.